Trials / Terminated
TerminatedNCT02622763
Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment
Safety and Clinical Efficacy Evaluation of Intralesional Administration of Tolerogenic Dendritic Cells in Patients With Refractory Crohn's Disease
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment.
Detailed description
The main objective is to evaluate the safety and clinical response of intralesional injection of Autologous peripheral blood differentiated adult dendritic cells expanded tolerogenic in patients with refractory Crohn's disease treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Tolerogenic Dendritic Cells | Intralesional administration |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2019-05-05
- Completion
- 2019-05-05
- First posted
- 2015-12-04
- Last updated
- 2020-02-28
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT02622763. Inclusion in this directory is not an endorsement.